Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 24, 2008

Dainippon Sumitomo Pharma Taps BioSeek to Advance R&D in Inflammation and Metabolic Diseases

  • BioSeek and Dainippon Sumitomo Pharma (DSP) signed an agreement for R&D in inflammation and metabolic diseases. BioSeek will apply its BioMAP® Systems to support compound differentiation, lead development, and drug candidate selection activities for DSP’s discovery programs.

    BioMAP Systems are a series of human primary cell-based assays designed to replicate cell and pathway interactions present in human disease biology. BioMAP profiling provides insight into human pharmacological properties of compounds, including characterization of biological drug function, on- and off-target activities, and biomarker identification.

    “The BioMAP platform represents a very compelling approach to applying human systems biology to pharmaceutical research and development,” remarks Yuichi Yokoyama, M.D., executive director at DSP. “BioMAP Systems deliver otherwise difficult-to-obtain human biological information, which will help us prioritize leads and candidates.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »